oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Upcoming Events
-
MEDICA 2022 in Düsseldorf, Germany
14. November - 17. November
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
World Sexual Health Day: Cancer is also an issue
BlogThere are many more aspects to the topic of sexual health than are apparent at first glance. We want to use World Sexual Health Day as an opportunity to draw attention to cervical cancer, which develops from a sexually transmitted HPV infection. Definition of sexual health The World Health Organization (WHO) defines sexual health as […]
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Press ReleasesGynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. The product is the first approved methylation test for triage of HPV-positive cases in China. GynTect was developed by oncgnostics GmbH and is already approved […]
Early detection of vulvar and vaginal cancer is overdue
BlogThere is still no targeted method for early detection of vulvar and vaginal cancer. This is despite the fact that an estimated 45,240 women worldwide were diagnosed with vulvar cancer in 2020, and more than 17,000 people even died from it. Vaginal cancer occurs slightly less frequently – with around 18,000 new cases and 8,000 […]
The IVDR (In-vitro Diagnostic Medical Device Regulation)
BlogThe new IVDR (In-vitro Diagnostic Medical Device Regulation) has been in force since 26 May. As a result, numerous companies have had to adapt their approval processes and internal procedures. The new regulations also present oncgnostics with new challenges. For example, the molecular biological cancer tests now fall into the second highest risk level. This […]
PCR test detects cervical precancerous lesions
Blog, Press ReleasesJena, Germany, May 25th 2022 – May 28 marks the 35th International Day of Action for Women’s Health. One “female” disease that should no longer exist due to the availability of modern cancer-screening methods is cervical cancer. One step in the direction of abolishing this form of cancer has been taken by the German life […]
WHO recommends one-dose HPV vaccination for girls
BlogThe World Health Organisation (WHO) recommends the one-dose HPV vaccination of girls and women up to 21 years of age instead of the current two-time vaccination. The WHO wants to increase the vaccination rate in the fight against cervical cancer. In principle, we welcome this plan, but we also have reservations regarding the new recommendation[1]. […]
oncgnostics at EUROGIN 2022
BlogThe EUROGIN is THE event for our current application areas and most of the experts were in Düsseldorf. So were we! With four presentations oncgnostics participated in the scientific discourse at the International multidisciplinary HPV Congress. The congress was again a great opportunity for us to make new contacts, maintain existing partnerships and exchange ideas […]
Oncgnostics receives award: Germany’s most innovative companies
BlogThe business magazine Capital selected Germany’s most innovative companies for the third time. Oncgnostics GmbH made it into the selection. The biotech company scored particularly well in the evaluation criterion of innovation areas. For the third time, Capital, together with the market research institute Statista, determined Germany’s most innovative companies. For this purpose, they brought […]
A startup turns 10 – oncgnostics grows with its employees
Blog10 years ago a small, very motivated team founded the oncgnostics GmbH to improve cervical cancer screening. Since then, oncgnostics GmbH has been growing and with it the number of its employees. On the occasion of the anniversary, it is time to share the experiences of the employees of the biotech company. 10 years of […]
Cancer prevention remains a matter of the heart: Biotech company oncgnostics celebrates 10th anniversary
Press ReleasesThe company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in Europe and Asia. In addition, oncgnostics conducts research in the field of diagnostics for head and neck cancer. The company is growing steadily and has […]